Browse > Article
http://dx.doi.org/10.14348/molcells.2018.2311

AURKA Suppresses Leukemic THP-1 Cell Differentiation through Inhibition of the KDM6B Pathway  

Park, Jin Woo (Department of Life Science, College of Natural Sciences, Chung-Ang University)
Cho, Hana (Department of Life Science, College of Natural Sciences, Chung-Ang University)
Oh, Hyein (Department of Life Science, College of Natural Sciences, Chung-Ang University)
Kim, Ji-Young (Department of Life Science, College of Natural Sciences, Chung-Ang University)
Seo, Sang-Beom (Department of Life Science, College of Natural Sciences, Chung-Ang University)
Publication Information
Molecules and Cells / v.41, no.5, 2018 , pp. 444-453 More about this Journal
Abstract
Aberrations in histone modifications are being studied in mixed-lineage leukemia (MLL)-AF9-driven acute myeloid leukemia (AML). In this study, we focused on the regulation of the differentiation of the MLL-AF9 type AML cell line THP-1. We observed that, upon phorbol 12-myristate 13-acetate (PMA) treatment, THP-1 cells differentiated into monocytes by down-regulating Aurora kinase A (AURKA), resulting in a reduction in H3S10 phosphorylation. We revealed that the AURKA inhibitor alisertib accelerates the expression of the H3K27 demethylase KDM6B, thereby dissociating AURKA and YY1 from the KDM6B promoter region. Using Flow cytometry, we found that alisertib induces THP-1 differentiation into monocytes. Furthermore, we found that treatment with the KDM6B inhibitor GSK-J4 perturbed the PMA-mediated differentiation of THP-1 cells. Thus, we discovered the mechanism of AURKA-KDM6B signaling that controls the differentiation of THP-1 cells, which has implications for biotherapy for leukemia.
Keywords
AURKA; differentiation; KDM6B; MLL-AF9 AML; THP-1;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Valerio, D.G., Xu, H., Chen, C.W., Hoshii, T., Eisold, M.E., Delaney, C., Cusan, M., Deshpande, A.J., Huang, C.H., Lujambio, A., et al. (2017). Histone Acetyltransferase Activity of MOF Is Required for MLL-AF9 Leukemogenesis. Cancer Res. 77, 1753-1762.   DOI
2 van Haaften, G., Dalgliesh, G.L., Davies, H., Chen, L., Bignell, G., Greenman, C., Edkins, S., Hardy, C., O'Meara, S., Teague, J., et al. (2009). Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat. Genet. 41, 521-523.   DOI
3 Van Hooser, A., Goodrich, D.W., Allis, C.D., Brinkley, B.R., and Mancini, M.A. (1998). Histone H3 phosphorylation is required for the initiation, but not maintenance, of mammalian chromosome condensation. J. Cell Sci. 111 ( Pt 23), 3497-3506.
4 Venkataraman, S., Alimova, I., Tello, T., Harris, P.S., Knipstein, J.A., Donson, A.M., Foreman, N.K., Liu, A.K., and Vibhakar, R. (2012). Targeting Aurora Kinase A enhances radiation sensitivity of atypical teratoid rhabdoid tumor cells. J. Neurooncol. 107, 517-526.   DOI
5 Warrell, R.P., Jr. (1999). Arsenicals and inhibitors of histone deacetylase as anticancer therapy. Haematologica 84 Suppl EHA-4, 75-77.
6 Zhao, W., Li, Q., Ayers, S., Gu, Y., Shi, Z., Zhu, Q., Chen, Y., Wang, H.Y., and Wang, R.F. (2013). Jmjd3 inhibits reprogramming by upregulating expression of INK4a/Arf and targeting PHF20 for ubiquitination. Cell 152, 1037-1050.   DOI
7 Zuber, J., Shi, J., Wang, E., Rappaport, A.R., Herrmann, H., Sison, E.A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., et al. (2011). RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478, 524-528.   DOI
8 Rountree, M.R., Bachman, K.E., and Baylin, S.B. (2000). DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat. Genet. 25, 269-277.   DOI
9 Agger, K., Cloos, P.A., Christensen, J., Pasini, D., Rose, S., Rappsilber, J., Issaeva, I., Canaani, E., Salcini, A.E., and Helin, K. (2007). UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nature 449, 731-734.   DOI
10 Asada, M., Yamada, T., Ichijo, H., Delia, D., Miyazono, K., Fukumuro, K., and Mizutani, S. (1999). Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation. EMBO J. 18, 1223-1234.   DOI
11 Auwerx, J. (1991). The human leukemia cell line, THP-1: a multifacetted model for the study of monocyte-macrophage differentiation. Experientia 47, 22-31.   DOI
12 Crosio, C., Fimia, G.M., Loury, R., Kimura, M., Okano, Y., Zhou, H., Sen, S., Allis, C.D., and Sassone-Corsi, P. (2002). Mitotic phosphorylation of histone H3: spatio-temporal regulation by mammalian Aurora kinases. Mol. Cell. Biol. 22, 874-885.   DOI
13 Cantu, C., Ierardi, R., Alborelli, I., Fugazza, C., Cassinelli, L., Piconese, S., Bose, F., Ottolenghi, S., Ferrari, G., and Ronchi, A. (2011). Sox6 enhances erythroid differentiation in human erythroid progenitors. Blood 117, 3669-3679.   DOI
14 Chang, E., Ganguly, S., Rajkhowa, T., Gocke, C.D., Levis, M., and Konig, H. (2016). The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells. Leukemia 30, 1025-1032.   DOI
15 Chen, C.W., Koche, R.P., Sinha, A.U., Deshpande, A.J., Zhu, N., Eng, R., Doench, J.G., Xu, H., Chu, S.H., Qi, J., et al. (2015). DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia. Nat. Med. 21, 335-343.   DOI
16 Daigle, S.R., Olhava, E.J., Therkelsen, C.A., Basavapathruni, A., Jin, L., Boriack-Sjodin, P.A., Allain, C.J., Klaus, C.R., Raimondi, A., Scott, M.P., et al. (2013). Potent inhibition of DOT1L as treatment of MLLfusion leukemia. Blood 122, 1017-1025.   DOI
17 Fuks, F., Burgers, W.A., Brehm, A., Hughes-Davies, L., and Kouzarides, T. (2000). DNA methyltransferase Dnmt1 associates with histone deacetylase activity. Nat. Genet. 24, 88-91.   DOI
18 Gautschi, O., Heighway, J., Mack, P.C., Purnell, P.R., Lara, P.N., Jr., and Gandara, D.R. (2008). Aurora kinases as anticancer drug targets. Clin. Cancer Res. 14, 1639-1648.   DOI
19 Gorgun, G., Calabrese, E., Hideshima, T., Ecsedy, J., Perrone, G., Mani, M., Ikeda, H., Bianchi, G., Hu, Y., Cirstea, D., et al. (2010). A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood 115, 5202-5213.   DOI
20 Gilan, O., Lam, E.Y., Becher, I., Lugo, D., Cannizzaro, E., Joberty, G., Ward, A., Wiese, M., Fong, C.Y., Ftouni, S., et al. (2016). Functional interdependence of BRD4 and DOT1L in MLL leukemia. Nat. Struct. Mol. Biol. 23, 673-681.   DOI
21 Gu, J., Gong, Y., Huang, M., Lu, C., Spitz, M.R., and Wu, X. (2007). Polymorphisms of STK15 (Aurora-A) gene and lung cancer risk in Caucasians. Carcinogenesis 28, 350-355.
22 Han, A., Chae, Y.C., Park, J.W., Kim, K.B., Kim, J.Y., and Seo, S.B. (2015). Transcriptional repression of ANGPT1 by histone H3K9 demethylase KDM3B. BMB Rep. 48, 401-406.   DOI
23 Hendzel, M.J., Wei, Y., Mancini, M.A., Van Hooser, A., Ranalli, T., Brinkley, B.R., Bazett-Jones, D.P., and Allis, C.D. (1997). Mitosisspecific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. Chromosoma 106, 348-360.   DOI
24 Hong, S., Cho, Y.W., Yu, L.R., Yu, H., Veenstra, T.D., and Ge, K. (2007). Identification of JmjC domain-containing UTX and JMJD3 as histone H3 lysine 27 demethylases. Proc. Natl. Acad. Sci. USA 104, 18439-18444.   DOI
25 Messeguer, X., Escudero, R., Farre, D., Nunez, O., Martinez, J., and Alba, M.M. (2002). PROMO: detection of known transcription regulatory elements using species-tailored searches. Bioinformatics 18, 333-334.   DOI
26 Hsu, J.Y., Sun, Z.W., Li, X., Reuben, M., Tatchell, K., Bishop, D.K., Grushcow, J.M., Brame, C.J., Caldwell, J.A., Hunt, D.F., et al. (2000). Mitotic phosphorylation of histone H3 is governed by Ipl1/aurora kinase and Glc7/PP1 phosphatase in budding yeast and nematodes. Cell 102, 279-291.   DOI
27 Huang, X.F., Luo, S.K., Xu, J., Li, J., Xu, D.R., Wang, L.H., Yan, M., Wang, X.R., Wan, X.B., Zheng, F.M., et al. (2008). Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia. Blood 111, 2854-2865.   DOI
28 Kim, S.R., Kim, K.B., Chae, Y.C., Park, J.W., and Seo, S.B. (2016). H3S10 phosphorylation-mediated transcriptional regulation by Aurora kinase A. Biochem. Biophys. Res. Commun. 469, 22-28.   DOI
29 Krivtsov, A.V., and Armstrong, S.A. (2007). MLL translocations, histone modifications and leukaemia stem-cell development. Nat. Rev. Cancer 7, 823-833.   DOI
30 Liu, Q., and Ruderman, J.V. (2006). Aurora A, mitotic entry, and spindle bipolarity. Proc. Natl. Acad. Sci. USA 103, 5811-5816.   DOI
31 Meyer, C., Hofmann, J., Burmeister, T., Groger, D., Park, T.S., Emerenciano, M., Pombo de Oliveira, M., Renneville, A., Villarese, P., Macintyre, E., et al. (2013). The MLL recombinome of acute leukemias in 2013. Leukemia 27, 2165-2176.   DOI
32 Meyer, C., Kowarz, E., Hofmann, J., Renneville, A., Zuna, J., Trka, J., Ben Abdelali, R., Macintyre, E., De Braekeleer, E., De Braekeleer, M., et al. (2009). New insights to the MLL recombinome of acute leukemias. Leukemia 23, 1490-1499.   DOI
33 Nowak, D., Stewart, D., and Koeffler, H.P. (2009). Differentiation therapy of leukemia: 3 decades of development. Blood 113, 3655-3665.   DOI
34 Oh, S.T., Kim, K.B., Chae, Y.C., Kang, J.Y., Hahn, Y., and Seo, S.B. (2014). H3K9 histone methyltransferase G9a-mediated transcriptional activation of p21. FEBS Lett. 588, 685-691.   DOI
35 Ota, T., Suto, S., Katayama, H., Han, Z.B., Suzuki, F., Maeda, M., Tanino, M., Terada, Y., and Tatsuka, M. (2002). Increased mitotic phosphorylation of histone H3 attributable to AIM-1/Aurora-B overexpression contributes to chromosome number instability. Cancer Res. 62, 5168-5177.
36 Plass, C., Oakes, C., Blum, W., and Marcucci, G. (2008). Epigenetics in acute myeloid leukemia. Semin. Oncol. 35, 378-387.   DOI
37 Smetana, K., Mikulenkova, D., and Klamova, H. (2011). Heterochromatin density (condensation) during cell differentiation and maturation using the human granulocytic lineage of chronic myeloid leukaemia as a convenient model. Folia Biol. 57, 216-221.
38 Sakakura, C., Hagiwara, A., Yasuoka, R., Fujita, Y., Nakanishi, M., Masuda, K., Shimomura, K., Nakamura, Y., Inazawa, J., Abe, T., et al. (2001). Tumour-amplified kinase BTAK is amplified and overexpressed in gastric cancers with possible involvement in aneuploid formation. Br. J. Cancer 84, 824-831.   DOI
39 Sehdev, V., Peng, D., Soutto, M., Washington, M.K., Revetta, F., Ecsedy, J., Zaika, A., Rau, T.T., Schneider-Stock, R., Belkhiri, A., et al. (2012). The aurora kinase A inhibitor MLN8237 enhances cisplatininduced cell death in esophageal adenocarcinoma cells. Mol. Cancer Ther. 11, 763-774.   DOI
40 Shechter, D., Dormann, H.L., Allis, C.D., and Hake, S.B. (2007). Extraction, purification and analysis of histones. Nat. Protoc. 2, 1445-1457.   DOI
41 Son, H.J., Kim, J.Y., Hahn, Y., and Seo, S.B. (2012). Negative regulation of JAK2 by H3K9 methyltransferase G9a in leukemia. Mol. Cell. Biol. 32, 3681-3694.   DOI
42 Sugarman, J.L., Schonthal, A.H., and Glass, C.K. (1995). Identification of a cell-type-specific and E2F-independent mechanism for repression of cdc2 transcription. Mol. Cell. Biol. 15, 3282-3290.   DOI
43 Tonelli, R., Sartini, R., Fronza, R., Freccero, F., Franzoni, M., Dongiovanni, D., Ballarini, M., Ferrari, S., D'Apolito, M., Di Cola, G., et al. (2006). G1 cell-cycle arrest and apoptosis by histone deacetylase inhibition in MLL-AF9 acute myeloid leukemia cells is p21 dependent and MLL-AF9 independent. Leukemia 20, 1307-1310.   DOI